Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Assets (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Non-Current Assets for 6 consecutive years, with -$155.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets changed N/A to -$155.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $134.1 million, a N/A change, with the full-year FY2024 number at $93.9 million, up 0.61% from a year prior.
  • Non-Current Assets was -$155.5 million for Q3 2025 at Caribou Biosciences, down from $93.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $113.5 million in Q4 2022 to a low of -$155.5 million in Q3 2025.
  • A 5-year average of $50.4 million and a median of $78.0 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 343.55% in 2022, then dropped 17.75% in 2023.
  • Caribou Biosciences' Non-Current Assets stood at $51.2 million in 2021, then skyrocketed by 121.87% to $113.5 million in 2022, then dropped by 17.75% to $93.4 million in 2023, then rose by 0.61% to $93.9 million in 2024, then tumbled by 265.54% to -$155.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Non-Current Assets are -$155.5 million (Q3 2025), $93.9 million (Q4 2024), and $102.3 million (Q1 2024).